- Lobbying
- Lobbying by PHARMACEUTICAL DISTRIBUTION SECURITY ALLIANCE
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Vincent Ventimiglia Jr | ASSIST SEC'Y FOR LEGISLATION, HHS Assist. Secretary for Legislation - HHS Assist. Sec for Legislation - HHS ASSIST. SECRETARY OF LEGISLATION, HHS |
Elizabeth Wroe | HEALTH POLICY DIRECTOR, SENATE COMM. ON BUDGET Health/Policy director/counsel, Comm. on Budget |
Vince Ventimiglia Jr | Assist. Secretary for Legislation - HHS |
Robert Ehrich | n/a |
Anne Marie Polak | n/a |
Elizabeth Baney | n/a |
Philip Bonforte | n/a |
VINCENT VENTIMIGLIA | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Food & Drug Administration (FDA)
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Food & Drug Administration (FDA)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Food & Drug Administration (FDA)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Food & Drug Administration (FDA)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Food & Drug Administration (FDA)
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Food & Drug Administration (FDA)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Food & Drug Administration (FDA)
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
U.S. Senate
Food & Drug Administration (FDA)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Food & Drug Administration (FDA)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Registration
Issue(s) they said they’d lobby about: PHARMACEUTICAL DISTRIBUTION AND SUPPLY CHAIN SECURITY.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate